- Trial phase
- Approved
- Time to market
- Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
- Why 7/10
- The next hard, dated catalyst is the FDA PDUFA decision on November 14, 2026 (tomorrow) for the supplemental NDA based on the MAPLE-HCM trial, which could expand the label for aficamten in obstructive HCM. Since the drug is already approved and generating revenue, this is a label-expansion binary rather than a make-or-break event, but it is the company's lead asset and the catalyst is imminent, supporting a score of 7.
The FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.
Price Chart
Executive Summary
MYQORZO (aficamten) is Cytokinetics' first approved drug, a cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM). It received FDA approval in December 2025 for symptomatic obstructive HCM and Health Canada approval in October 2026. The drug generated $44.5 million in Q3 2026 net revenue (76% sequential growth). The next major catalyst is a PDUFA decision on November 14, 2026 for a supplemental NDA based on the MAPLE-HCM trial, which showed aficamten's superiority over the standard beta blocker metoprolol. Separately, the Phase 3 ACACIA-HCM trial in non-obstructive HCM (a condition with no approved treatments) met both primary endpoints, and a supplemental NDA submission is expected in Q4 2026. Analyst consensus is strongly bullish with a mean price target of $109.42, implying roughly 95% upside from the current ~$56 share price.
How It Works
Aficamten is a cardiac myosin inhibitor. It works by reducing the force of contraction of the heart muscle. In hypertrophic cardiomyopathy, the heart muscle becomes abnormally thick, making it harder for the heart to pump blood. By inhibiting the cardiac myosin protein (the motor that drives heart muscle contraction), aficamten reduces excessive contraction, improves blood flow, and relieves symptoms like shortness of breath and chest pain.
Trial Status
MYQORZO is FDA-approved for symptomatic obstructive HCM (based on SEQUOIA-HCM Phase 3 trial) and Health Canada-approved. The MAPLE-HCM Phase 3 trial (aficamten vs. metoprolol in oHCM) met its primary endpoint and supports a pending sNDA with a PDUFA date of November 14, 2026. The ACACIA-HCM Phase 3 trial in non-obstructive HCM met both dual primary endpoints, with full results presented at ESC Congress 2026 and additional data at HFSA 2026 and HCMS/AHA 2026. A real-world study (ASPEN-HCM) launched in September 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision on MAPLE-HCM sNDA: November 14, 2026 (label expansion for oHCM)
- Supplemental NDA submission for non-obstructive HCM (ACACIA-HCM): expected Q4 2026
- Type II Variation submission in the European Union: expected early 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CYTOKINETICS INC CLUSTER CYTK ·Originating report